GSK: 3 Key Takeaways for Long-Term Investors
Cost discipline is offsetting R&D investment without squeezing margins, the financial foundation for sustained portfolio transformation.
GSK's third-quarter 2026 earnings call on October 28, 2026, highlighted three key takeaways for long-term investors. The company reaffirmed its full-year 2026 guidance, with sales growing 5% to £8.9 billion, signaling a successful transition from primary-care treatments to high-margin specialty therapies.
One significant development is GSK's accelerated research and development (R&D) pipeline. The company initiated 18 phase 3 clinical trials in 2026 and aims to reach 22 by the end of the year. This strategic focus on late-stage drug development is generating long-term organic growth for the company.
Specialty medicines also played a crucial role in GSK's performance, with a 15% increase in the third quarter. These higher-margin therapies counteracted broader price pressures in the inhaler market. Cabenuva, the only long-acting injectable regimen for HIV treatment, established a strong foundation among patients who prefer less frequent medication use.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.